Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502872 · ClinicalTrials.gov registry record · Phase 2
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
A Phase 2 study, sponsored by Brown University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07502872 is a Phase 2 study that has not yet begun recruiting, run by Brown University. The registered enrollment target is 30 participants.
The verdict
NCT07502872, a Phase 2 study, has not yet begun recruiting, sponsored by Brown University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Polatuzumab vedotin
- DRUG Tafasitamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07502872
The ClinicalTrials.gov registry entry for NCT07502872 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT07502872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07502872 about?
NCT07502872 is a clinical study titled "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma". This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
What is the current status of trial NCT07502872?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-05-01. Estimated completion is 2029-12-01.
What interventions are being tested in trial NCT07502872?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Polatuzumab vedotin (DRUG), Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT07502872?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.